Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis

Background: The potency and safety of toripalimab combination with chemotherapy (TC) as the first-line therapy for advanced non-small cell lung cancer (NSCLC) have been demonstrated in the CHOICE-01 study. Our research explored whether TC was cost-effective compared to chemotherapy alone from the Ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Huo, Gengwei, Liu, Wenjie, Kang, Shuo, Chen, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971805/
https://www.ncbi.nlm.nih.gov/pubmed/36865925
http://dx.doi.org/10.3389/fphar.2023.1131219

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971805/
https://www.ncbi.nlm.nih.gov/pubmed/36865925
http://dx.doi.org/10.3389/fphar.2023.1131219

Ejemplares similares